Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Portfolio expansion solidifies company's commitment to advancing cancer research and patient care BURLINGTON, N.C. , April 8, 2024 /PRNewswire/ --  Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision

New Vivarium Wing in Münster

Immuno-oncology. Biologics. Cell and gene therapies. This is the future of medicine. It’s more personalized, more complex and driving an increase in demand for highly technical nonclinical studies that require study models that most closely resemble the human body. Oftentimes, it’s nascent science that demands a new study that hasn’t even been invented yet.

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

Labcorp Plasma Detect is the first clinically validated, whole-genome sequencing MRD solution for early-stage colon cancer BURLINGTON, N.C. , April 5, 2024 /PRNewswire/ -- Labcorp  (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of

How to help reduce employee stress and improve their physical and mental health

April is National Stress Awareness Month and a great time to take stock on common stressors in life. It may seem counterintuitive, but some stress is actually good. It motivates us to get things done and can be used as an opportunity to grow, change direction or start over.Unfortunately, the volume and impact of negative stress are extensive—and costly.

Colorectal cancer: How to increase screening compliance rates

Watch subject matter experts Aasma Shaukat, MD, MPH, and Erin Peterson from the Colon Cancer Coalition address how to capture patient compliance for colorectal cancer screenings, gain early detection and improve patient outcomes.